Skip to main content
Download PDF

Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells

Journal of Translational Medicine volume 21, Article number: 328 (2023) Cite this article

Abstract

Background

Oral squamous cell carcinoma (OSCC) is one of the most prevalent and fatal oral cancers. Mitochondria-targeting therapies represent promising strategies against various cancers, but their applications in treating OSCC are limited. Alantolactone (ALT) possesses anticancer properties and also regulates mitochondrial events. In this study, we explored the effects of ALT on OSCC and the related mechanisms.

Methods

The OSCC cells were treated with varying concentrations and duration of ALT and N-Acetyl-l-cysteine (NAC). The cell viability and colony formation were assessed. The apoptotic rate was evaluated by flow cytometry with Annexin V-FITC/PI double staining. We used DCFH-DA and flow cytometry to detect reactive oxygen species (ROS) production and DAF-FM DA to investigate reactive nitrogen species (RNS) level. Mitochondrial function was reflected by mitochondrial reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and ATP levels. KEGG enrichment analyses determined the mitochondrial-related hub genes involved in OSCC progression. Dynamin-related protein 1 (Drp1) overexpression plasmids were further transfected into the cells to analyze the role of Drp1 in OSCC progression. Immunohistochemistry staining and western blot verified the expression of the protein.

Results

ALT exerted anti-proliferative and pro-apoptosis effects on OSCC cells. Mechanistically, ALT elicited cell injury by promoting ROS production, mitochondrial membrane depolarization, and ATP depletion, which were reversed by NAC. Bioinformatics analysis showed that Drp1 played a crucial role in OSCC progression. OSCC patients with low Drp1 expression had a higher survival rate. The OSCC cancer tissues presented higher phosphorylated-Drp1 and Drp1 levels than the normal tissues. The results further showed that ALT suppressed Drp1 phosphorylation in OSCC cells. Moreover, Drp1 overexpression abolished the reduced Drp1 phosphorylation by ALT and promoted the cell viability of ALT-treated cells. Drp1 overexpression also reversed the mitochondrial dysfunction induced by ALT, with decreased ROS production, and increased mitochondrial membrane potential and ATP level.

Conclusions

ALT inhibited proliferation and promoted apoptosis of oral squamous cell carcinoma cells via impairment of mitochondrial homeostasis and regulation of Drp1. The results provide a solid basis for ALT as a therapeutic candidate for treating OSCC, with Drp1 being a novel therapeutic target in treating OSCC.

Introduction

Oral squamous cell carcinoma (OSCC) is one of the most common malignant head and neck carcinomas [1]. Each year, the number of new OSCC cases exceeds 370,000, with approximately 170,000 people dying from OSCC [2]. OSCC is initially characterized by asymptomatic hyperplastic lesions on the tongue, buccal mucosa, and gingiva [3]. The majority of cases are diagnosed at advanced stages with poor prognosis [4], high recurrence rates [5], and resistance to traditional therapy [6]. The 5-year survival rate of OSCC patients is only 60% despite the comprehensive and multidisciplinary therapeutic approaches [7, 8]. A thorough understanding of the pathological etiology of OSCC progression is urgently required for developing effective therapeutic strategies.

Oxidative stress (OS) refers to redox imbalance characterized by excessive reactive oxygen species (ROS) and reactive nitrogen species (RNS) [9]. Oxidative damage to DNA, proteins, and lipids significantly contributes to cancer formation and progression [10]. Additionally, antioxidants targeting ROS were long considered defensive weapons in preventing cancer development [11]. ROS are primarily generated in mitochondria, which is also the principal target of OS [12]. The multiple critical roles of mitochondria in cancer progression make them important targets for anticancer therapy [13].

Mitochondria-targeting therapies represent promising treatments for colon cancer [14] and breast cancer [15]. The underlying mechanisms include ROS regulation, mitochondrial DNA (mtDNA) interference, and mitophagy induction [13, 16, 17]. However, studies on mitochondrial-targeting therapy for OSCC are limited and need further exploration.

As a compound derived from Inula Racemosa, alantolactone (ALT) possesses numerous biological properties, including anti-inflammatory and antibacterial [18], antioxidant [19], and anticancer effects [20]. Additionally, studies have confirmed that ALT prevented cancer progression through regulation of mitochondria [21, 22]. ALT induced ROS production [23], promoted ROS-mediated mitochondrial dysfunction [21], and triggered mitochondrial-mediated apoptosis [24] in cancers involving the liver [25], lung [26], and breast [21, 27]. However, whether ALT inhibits OSCC progression and the underlying mechanism remains elusive. We aimed to evaluate the effects of ALT on OSCC and the involved mechanisms. The results revealed that ALT elicited OSCC cell death via ROS-mediated mitochondrial impairment and suppression of dynamin-related protein 1 (Drp1) phosphorylation. Our findings provide evidence that ALT is a promising therapeutic agent against OSCC. Furthermore, targeting mitochondria and Drp1 may be promising treatment modalities against OSCC.

Methods

Materials

The cell culture medium was from Life Technologies (Grand Island, NY, USA). Antibodies against Drp1 (sc-271583, Santa Cruz, CA, USA) and translocase of the outer membrane 20 (TOM20) (sc-17764, Santa Cruz, CA, USA), the phosphorylated-Drp1 (p-Drp1) antibody (AF8470, Affinity Biosciences, USA), the voltage-dependent anion channel 1 (VDAC1) antibody (ab14734, Abcam, Cambridge, UK), GAPDH (10494-1-AP, Proteintech Group, China) and secondary antibody (SA00001-2, Proteintech Group, China) were used. ALT (A114070, Aladdin Industrial Corporation, China) and N-acetyl-cysteine (NAC) (A7250, Sigma, USA) were applied.

Cell culture and treatment

The human OSCC cells, including CAL27 and SCC9 cells, were from Wuhan University. CAL27 cells were cultured in DMEM and SCC9 cells were cultured in F-12K medium. Cells were cultured at 37 °C with 5% CO2. When the cells achieved 80% confluency, they were passaged and digested with trypsin. Cultured cells were treated with ALT of different concentrations and duration time. For experiments with NAC, the cells were pre-treated with 5 mM NAC for 2 h, according to the previous studies [28, 29].

Drp1 overexpressed plasmids were transfected into cells to explore the role of Drp1 in OSCC progression. The cells were inoculated into a 6-well plate and transfected with control and Drp1 overexpressed plasmids. All transfections were performed using Lipofectamine 3000 (L3000008, Invitrogen, USA) according to the manufacturer’s instructions [30]. Transfection efficiency was confirmed by western blot.

Cell viability assay

We adopted the Methyl thiazolyl tetrazolium (MTT) assay to assess the cell viability. Cells were seeded in a 96-well plate at a density of 4500 cells/well in a volume of 100 μL/well. After incubating with MTT, dimethyl sulfoxide was added to the cells to dissolve the formazan crystals. The spectrophotometric absorbance was measured at 490 nm. The average absorbance of the control DMSO group was set at 100%, and the absorbance ratio reflected the cell viability.

Western blot analysis

Cells were seeded in a 6-well plate at 2 × 105 cells/well density and cultured under different conditions. Total proteins were collected using RIPA buffer (P0013, Beyotime, China), the concentrations of which were determined using the Bradford protein assay kit (23236, Thermo Fisher Scientific, USA). During the electrophoresis, we loaded 60–80 µg proteins in each slot in the SDS gel. Protein gels were blotted using the Trans-Blot Turbo transfer apparatus and PVDF Midi transfer packs (Bio-Rad). After blocking with 5% non-fat milk in TBST, blots were incubated with the primary antibodies with anti-p-Drp1 (1:1000), anti-Drp1 (1: 1000), and anti-GAPDH (1:20,000). After further incubation with secondary antibodies, blots were developed with ECL substrate (32209, Thermo Fisher Scientific, USA). NIH Image J software (https://imagej.nih.gov/ij/) detected the immunoreactive band relative to the optical density.

Determination of intracellular ROS and RNS

2,7-Dichlorofluorescein diacetate (DCFH-DA) (S0033, Beyotime, China) was used to evaluate the intracellular ROS production. 3-amino,4-aminomethyl-2′,7′-fluorescein diacetate (DAF-FM DA) (S0019, Beyotime, China) was used to detect intracellular RNS level [31]. After treatment, the cells were stained with either DCFH-DA or DAF-FM DA for 20 min and rinsed with PBS. Images were taken by fluorescence microscope (Nikon, Japan) and evaluated by NIH Image J software (https://imagej.nih.gov/ij/).

Mitochondria functional and morphology imaging assays

Cells were incubated with MitoSOX red to detect mitochondrial ROS (mtROS). Additionally, mitochondrial membrane potential (MMP) was evaluated with the tetramethylrhodamine methyl ester dye (TMRM). We detected the fluorescence signals of MitoSOX (M36006, Thrmofisher, USA), TMRM (I34361, Thrmofisher, USA), and MitoGreen (M36008, Thrmofisher, USA) at the excitation/emission wavelengths of 357/410 nm, 548/574 nm, and 491/513 nm. Fluorescence signals were measured using NIH Image J software.

Colony outgrowth assay

Crystal violet (0.5% in 25% methanol) was used to stain the cells under different treatment conditions. A microscope (Olympus, Japan) was used to record the images. The colony formation areas were evaluated by Image J software (https://imagej.nih.gov/ij/).

Annexin V-FITC/propidium iodide (PI) staining assay

An Annexin V-FITC/PI (C1062, Beyotime, China) apoptosis detection kit was adopted to detect the apoptotic rate. After trypsin digestion without ethylene diamine tetraacetic acid, the cells were collected by centrifugation and re-suspended. Annexin V-FITC and PI were added to the cell suspension in an ice bath. These staining conditions were examined by flow cytometer (CytoFLEX; Beckman Coulter, USA).

Adenosine triphosphate (ATP) synthesis assays

ATP is primarily produced through oxidative phosphorylation in mitochondria and thus represents an essential indicator of mitochondrial function [32]. The CellTiter-Glo Assay evaluated ATP production. 100 µL of ATP detection buffer was added into each well. The luminescence was measured after 10 min of incubation, and the ATP level was normalized based on protein concentration.

Immunohistochemistry staining

The specimens were formalin-fixed, paraffin-embedded, and cut into sheets of 4 µm. Gradient alcohol dehydrated the tissue slides after they were dewaxed with xylene. The sections were added with diluted primary antibody against p-Drp1 (1:200), Drp1 (1:200), TOM20 (1:200), and VDAC1 (1:200). Nuclei were counterstained with hematoxylin and then sealed in neutral rubber. In the final step, the sections were viewed under a light microscope.

Patient samples and ethics

Wenzhou Medical University’s Research Ethics Committee approved protocol KY2022-R156 for this clinical-laboratory study. From October 2020 to December 2021, samples were obtained from 20 paired cancer tissues and adjacent tissues from patients at the Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital of Wenzhou Medical University. Inclusion criteria were: (1) Patients complied with the Head and Neck Cancers Clinical Practice Guidelines [33]. (2) None of the patients had previously been treated with chemotherapy or radiotherapy. (3) The patients have no other malignancy or autoimmune diseases.

Bioinformatics method

The RNA-seq transcriptome data of 500 head and neck squamous cell carcinoma tissues, 44 adjacent normal tissues and corresponding clinical data were obtained from the Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) database. MitoCarta2.0 documented the biological pathways and gene sets related to mitochondrial metabolism and thus was used in our study. Single-sample gene set enrichment analysis was used to calculate the infiltrating scores of mitochondrial-related metabolic pathways based on the above information. A protein–protein interaction (PPI) network was constructed using the Interacting Gene Retrieval Search tool (https://string-db.org/) to evaluate the interactions of mitochondrial metabolic pathways-related genes (MMPRGs). MMPRGs with |log Fold Change| > 0.5 and an adjusted p-value < 0.05 were identified as differentially expressed MMPRGs. Genes were further evaluated for prognostic significance with univariate cox regression analysis.

Statistical analyses

Data analysis was performed with GraphPad Prism 8.0. Analyses of variance were performed to evaluate the data, expressing it as mean ± SD. Statistics were significant when p < 0.05. Six photographic fields were detected from all the figures and used for analysis. Each experiment was repeated three times. All bioinformatic analyses were conducted by packages and appropriate scripts in R (version 4.2.1) (http://www.R-project.org).

Results

ALT exhibited anti-proliferative and pro-apoptotic effects on OSCC cells

Alantolactone (ALT) is a natural sesquiterpene lactone isolated from Inula helenium (Fig. 1A). We examined the effects of ALT on various types of cancer cells, including non-small cell lung cancer cell line PC-9, human LoVo colon cancer line, human glioblastoma cell lines U251, and the OSCC cell lines with CAL27 and SCC9 cells. The results showed that the OSCC cells were more sensitive to ALT than the other cancer subtypes (Fig. 1B), suggesting the strong inhibitory effect of ALT on OSCC. We further investigated the effects of ALT on CAL27 and SCC9 cell lines at different time intervals. ALT reduced the cell viability in a time-dependent way, with lower viability early at 12 h than the control group (Fig. 1C, D). In addition, ALT-treated cells formed smaller and fewer clones than their control counterparts in colony outgrowth assays (Fig. 1E–G). Taken together, ALT inhibited cell proliferation and colony formation abilities, which are essential for the formation of OSCC. We further explored the impact of ALT on the cell apoptosis rate of CAL27 and SCC9 cells. ALT increased the apoptotic rate of CAL27 and SCC9 cells, respectively, from 18.52 to 66% and from 2.81 to 49.75% (Fig. 1H–K).

Fig. 1
figure 1

ALT inhibited cell viability and triggered OSCC cell apoptosis. A Chemical structure of ALT. B The inhibitory effects of ALT on PC-9, LOVO, U251, CAL27, and SCC9 cells. C, D Cell viability was measured in CAL27 and SCC9 cells after being treated with ALT for 24 h. E, F Cell viability was measured in CAL27 and SCC9 cells after being treated with ALT for indicated periods. G–I CAL27 and SCC9 cells were seeded into 6-well plates and then treated with various dosages of ALT as indicated. The number of colonies was assessed and quantified by crystal violet staining. J–M Flow cytometry analysis after Annexin V-FITC/PI double staining. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus the Control group)

Full size image

ROS regulation was essential in the preventive effects of ALT against OSCC cells

To check whether ALT affects CAL27 and SCC9 cells via the regulation of OS, we measured the cellular total ROS level with the fluorescent probe DCFH-DA. ROS levels increased dose-dependently after ALT treatment (Fig. 2A–C). We further measured the RNS level as an additional readout of OS through DAF-FM DA. ALT dose-dependently increased the RNS levels in CAL27 and SCC9 cells (Fig. 2D–F). We further used NAC, a ROS scavenger, to identify whether ROS mediates the anticancer property of ALT. Compared with the cells only treated with ALT, a combination of NAC pretreatment and ALT treatment resulted in significantly lower ROS production in CAL27 and SCC9 cells, as confirmed both by DCFH-DA staining and flow cytometry (Fig. 2G–I). Quantitative analysis of MTT and colony outgrowth assay also showed that cells cotreated with NAC and ALT presented a higher proliferation rate than the lean ALT treatment group (Fig. 3A–F). Furthermore, NAC treatments reduced ALT-induced cell apoptosis (Fig. 3G–J). These results strongly substantiated that ROS regulation played crucial roles in the inhibitory effects of ALT on CAL27 and SCC9 cells.

Fig. 2
figure 2

ROS regulation played a critical role in the preventive effect of ALT against OSCC cells. A–C Representative DCFH-DA fluorescent images in CAL27 and SCC9 cells treated with ALT. Mean optical density analysis of cellular DCFH-DA staining (green fluorescence; a ROS production indicator). Scale bar = 100 µm. D–F Representative DAF-FM DA fluorescent images in CAL27 and SCC9 cells treated with ALT. Mean optical density analysis of cellular DAF-FM DA staining (green fluorescence; an indicator of production of RNS). Scale bar = 100 µm. G–I Representative DCFH-DA fluorescent images in CAL27 and SCC9 cells treated with ALT with or without NAC. For experiments with NAC, the cells were pre-treated as with 5 mM NAC for 2 h. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. (***p < 0.001, ****p < 0.0001 versus the Control group, ####p < 0.0001 versus the ALT group)

Full size image
Fig. 3
figure 3

ROS regulation played a critical role in the preventive effect of ALT against OSCC cells. A–C Cell morphology observed by phase contrast microscope and cell viability analysis (scale bar = 100 µm). D–F The number of colonies assessed and quantified by crystal violet staining. G–J Flow cytometry-based Annexin V-FITC/PI labeling of apoptotic cells. We used 15 µM ALT to treat CAL27 cells and SCC9 cells. (**p < 0.01, ***p < 0.001, ****p < 0.0001 versus the Control group, #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus the ALT group)

Full size image

Mitochondrial abnormalities participated in the inhibitory effect of ALT against OSCC cells

Regarding the close relationship between ROS and mitochondria, it is necessary to investigate whether mitochondria play a role in the inhibitory effect of ALT on OSCC. ALT treatment decreased the ATP levels in CAL27 and SCC9 cells (Fig. 4A, B). To further explore whether ALT-induced ROS production was derived from mitochondria, we used MitoSOX to indicate the mtROS production. The results showed that after ALT treatment, mtROS production in CAL27 and SCC9 cells was vitally increased (Fig. 4C–F). Besides, TMRM staining indicated that ALT markedly decreased MMP (Fig. 4G–J). These results suggested that ALT induced remarkable mitochondrial impairment, as indicated by increased mtROS level and MMP loss.

Fig. 4
figure 4

Mitochondrial abnormalities were involved in the inhibitory effect of ALT against OSCC cells. A, B ATP production in the indicated groups. 10 µM ALT was used to treat CAL27 cells, and 4 µM ALT was added to SCC9 cells. C–F Representative images showing MitoSOX staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. G–J Representative images showing TMRM staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. (**p < 0.01, ***p < 0.001, ****p < 0.0001 versus the Control group)

Full size image

We further applied NAC to probe the specific role of ROS in regulating ALT-elicited mitochondrial impairment. NAC dramatically reversed the ALT-elicited ATP depletion in CAL27 and SCC9 cells (Fig. 5A, B). Furthermore, ALT increased the mtROS production, which was reversed by NAC cotreatment. These results suggested that ALT-induced intracellular ROS production was mainly derived from mitochondria (Fig. 5C–F). Moreover, Cells treated with NAC and ALT had significantly higher MMP levels than those only treated with ALT, indicating that NAC reversed the MMP loss induced by ALT (Fig. 5G–J). These experiments revealed that ROS-related mitochondrial abnormalities played a crucial role in the ALT-elicited CAL27 and SCC9 cell apoptosis.

Fig. 5
figure 5

Mitochondrial abnormalities were involved in the inhibitory effect of ALT against OSCC cells. A, B ATP production in the indicated groups. 10 µM ALT was used to treat CAL27 cells, and 4 µM ALT was added to SCC9 cells. C–F Representative images showing MitoSOX staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. G–J Representative images showing TMRM staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. (***p < 0.001, ****p < 0.0001 versus the Control group, #p < 0.05, ###p < 0.001, ####p < 0.0001 versus the ALT group)

Full size image

Mitochondrial regulatory proteins were associated with OSCC progression and the inhibitory effect of ALT against OSCC cells

To further explore the possible mitochondrial pathways involved in OSCC progression, we evaluated the gene expression patterns across diverse human OSCC and normal tissues with the TCGA database. Results showed that compared to the control group, mtDNA maintenance and mitochondrial dynamics were the two most differentially expressed pathways increased in the cancer tissues. Moreover, the pathways, such as amino acid metabolism and OXPHOS subunits, decreased significantly in the OSCC cancer tissues, which needs further exploration (Fig. 6A). Regarding the remarkable difference in mtDNA maintenance and mitochondrial dynamics between the normal and OSCC patients, we next focused on the possible mitochondrial regulating proteins involved in OSCC progression. Based on the STRING database, a PPI network of differentially expressed mitochondrial and mtDNA genes were constructed (Fig. 6B), and the top 20 proteins were obtained (Fig. 6C). Among the top 20 proteins, Drp1 (alias DNM1L), TOM20 (alias TOMM20), and VDAC1 differed significantly in cancer progression. Therefore, we further focused on the role of Drp1, TOM20, and VDAC1 in OSCC development. We collected cancer and normal tissues from 20 OSCC patients during surgery. ATP levels were strikingly higher in the cancer tissues than in the normal tissues (Fig. 6D). This result indicated that mitochondria played a crucial role in OSCC, as mitochondria are the primary source of ATP production. In OSCC cancer tissues, p-Drp1, Drp1, and TOM20 expressions increased significantly compared with normal tissues. Furthermore, the p-Drp1/Drp1 level increased significantly in the cancer samples (Additional file 1: Fig. S1). By contrast, the VDAC1 level was lower in OSCC cancer tissues than in normal tissues (Fig. 6E). Also, TCGA data revealed that OSCC patients with low Drp1 expression in cancer tissues had a higher overall survival rate than those with high Drp1 expression (p = 0.008) (Fig. 6F). More importantly, we explored whether Drp1 regulation participated in the inhibitory effects of ALT on OSCC cells. The results revealed that ALT dose-dependently downregulated the Drp1 phosphorylation level (Fig. 6G). We further investigated to explore the association between ROS generation and Drp1 dephosphorylation in the inhibitory effect of ALT on OSCC. The results confirmed that the ALT-induced decline of Drp1 dephosphorylation was reversed by NAC (Fig. 6H–J), indicating that ALT inhibited OSCC cell apoptosis by suppressing ROS-related Drp1 dephosphorylation.

Fig. 6
figure 6

Mitochondrial regulatory proteins associated with OSCC progression and inhibitory effect of ALT against OSCC cells. A TCGA database evaluated expression patterns across diverse head and neck squamous carcinoma and normal tissues. B Cancer protein target interaction network. C Protein interaction relationship histogram. D ATP synthesis detected in the indicated groups. E Images of immunohistochemistry staining for mitochondrial regulating proteins in adjacent non-cancer tissues and OSCC tissues. Scale bar = 50 µm. F Prognostic graphs illustrating the impact of Drp1 on overall survival in TCGA. G, H Western blot band of Drp1 protein expression after different treatments. I, J p-Drp1 level expressed relative to Drp1 level. (****p < 0.0001 versus the Normal tissue group, *p < 0.05 versus the Control group, #p < 0.05, ##p < 0.01 versus the ALT group)

Full size image

Drp1 participated in the inhibitory effect of ALT against OSCC cells

Drp1 overexpression abolished the reduced Drp1 phosphorylation by ALT (Fig. 7A–D) and promoted the cell viability reduced by ALT (Fig. 7E, F). Drp1 overexpression also reversed the mitochondrial dysfunction induced by ALT, with increased ATP level (Fig. 8A, B), decreased ROS production (Fig. 8C–F), and increased mitochondrial membrane potential (Fig. 8G–J) compared to the control group.

Fig. 7
figure 7

Drp1 is an important target of ALT against OSCC cells. A, B Western blot band of Drp1 protein expression after different treatments. We used 15 µM ALT to treat CAL27 cells and SCC9 cells. C, D p-Drp1 level relative to Drp1 level. E, F Cell viability was measured after being treated with ALT for 24 h. We used 10 µM ALT to treat CAL27 cells and 4 µM to treat SCC9 cells. (**p < 0.01, ***p < 0.001, ****p < 0.0001 versus the EV group, #p < 0.05, ####p < 0.0001 versus the EV + ALT group)

Full size image
Fig. 8
figure 8

High expression of Drp1 reversed the abnormal mitochondrial effect of ALT on OSCC cells. A, B ATP production in the indicated groups. 10 µM ALT was used to treat CAL27 cells, and 4 µM ALT was added to SCC9 cells. C–F Representative images showing MitoSOX staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. G–J Representative images showing TMRM staining and quantification in the indicated groups. 12 µM ALT was used to treat CAL27 cells, and 8 µM ALT was added to SCC9 cells. Scale bar = 100 µm. (***p < 0.001, ****p < 0.0001 versus the EV group, #p < 0.05, ###p < 0.001, ####p < 0.0001 versus the EV + ALT group)

Full size image

Discussion

In terms of malignancy rate and incidence, OSCC is one of the malignant oral carcinomas. Traditional therapies against OSCC, including surgery, chemotherapy, and radiotherapy, are sometimes ineffective because of drug resistance and side effects [7]. Hence, identifying novel and effective treatments is imperative. Mitochondria-targeting therapies have been proven effective in treating various cancers including the colon [14] and breast [15] cancers. However, studies on mitochondrial-targeting therapy for OSCC are limited and need further exploration. Our findings confirmed that ALT potently restrained the proliferation and triggered apoptosis of OSCC cells by inducing mtROS production, reducing MMP, and regulating Drp1 dephosphorylation.

OS is characterized by redox imbalances caused by the overproduction of ROS [9], which plays a vital role in developing various diseases [34]. In physiological conditions, the ROS accumulated in cells is rapidly eliminated by antioxidant enzymes. However, ROS are overproduced in pathological conditions, causing oxidative damage to biomolecules and worsening the cellular oxidative status [35]. Excessive ROS contribute to cancer development and can be used as therapeutic targets [36]. In our study, ALT reduced cell viability and enhanced apoptotic rate of OSCC cells by promoting ROS generation. Thus, ROS may be a promising therapeutic target for OSCC.

Mitochondria play a crucial part in cancer formation and progression [17]. Mitochondria have been recognized as the major source of ROS, which plays a critical role in cancer progression. Numerous studies have clarified the differences in mitochondria between normal and cancer cells, which might be used for cancer treatment [13,14,15, 21, 37]. Mitochondria-targeted therapies have been proven to be effective in preventing various cancers [38]. However, their application in OSCC treatment needs further exploration. In this study, the bioinformatics analysis revealed that mtDNA maintenance and mitochondrial dynamics were closely associated with OSCC. The expressions of mitochondrial proteins, including p-Drp1, Drp1, and TOM20, were notably higher in the cancer tissues of OSCC patients compared with the normal tissues. However, the expression of VDAC1 in OSCC tissues was lower than that in normal tissues. The specific role of these mitochondrial proteins in OSCC needs further exploration. Additionally, we elucidated that NAC effectively suppressed the mitochondrial membrane depolarization and mtROS production induced by NAC. NAC also blocked the ALT-elicited ROS production and cytotoxicity in CAL27 and SCC9 cells. These findings further indicated that ALT promoted CAL27 and SCC9 cell apoptosis by promoting ROS production and mitochondrial impairment.

ALT contains a wide variety of pharmacological properties, including anticancer [20], antibacterial [18], and anti-inflammatory activities [18]. Additionally, studies have proved that ALT prevented cancer progression via glutathione depletion, ROS induction [39], and mitochondrial impairment [21]. Our results also revealed that ALT induced cell death through the enhancement of ROS-mediated mitochondrial dysfunction in OSCC, implying mitochondrial-targeting therapy as a promising therapy strategy against OSCC. Drp1, the primary regulator of mitochondrial function and dynamics [40], is essential for developing various cancers [41]. The results illustrated that the p-Drp1 level increased vitally in the cancer tissues compared to the adjacent normal tissues. According to the bioinformatics analysis, OSCC patients with low Drp1 expressions had better overall survival than those with high Drp1 levels. Immunohistochemical results further confirmed that p-Drp1 and Drp1 increased significantly in OSCC cancer tissues compared to normal tissues. Furthermore, the cancer samples presented enhanced p-Drp1/Drp1 level, suggesting the essential role of Drp1 level and Drp1 phosphorylation in OSCC progression. In addition, ALT inhibited the Drp1 phosphorylation in OSCC cells. Our results further revealed that Drp1 overexpression abolished the reduced Drp1 phosphorylation by ALT and promoted the cell viability of ALT-treated cells. Drp1 overexpression also reversed the mitochondrial dysfunction induced by ALT. Taken together, ALT potentially induced OSCC cell apoptosis by downregulating Drp1 phosphorylation. ALT is a selective inhibitor of signal transducers and activators of transcription 3 (STAT3) [42]. Studies have shown that STAT3 is vital for Drp1 activation and mitochondrial fission [43,44,45]. Further studies are warranted to investigate whether STAT3 is an intermediate factor in the mitochondrial pathway mediated by ALT and Drp1.

To date, ALT has been used for treating various diseases through oral administration [21, 23,24,25]. However, the oral bioavailability of ALT is considerably low [46]. Nanostructured carriers entrapped with ALT have been used to improve bioavailability in treating cancers [47]. In most cases, OSCC mainly occurs at superficial sites [3]. Therefore, local applications of ALT-entrapped nanostructured gels or sprays represent promising treatment strategies for OSCC [48, 49].

Despite the critical results, this study has some limitations. Firstly, experiments were conducted only in CAL27 and SCC9 cells, while the normal cells were not involved. Further studies with normal cells are warranted. Additionally, the sample size was relatively small. More subjects should be enrolled to improve the reliability of our study. Finally, in vivo studies should be conducted to substantiate the in vitro results in future studies.

In summary, ALT induced OSCC cell apoptosis via enhancement of ROS-dependent mitochondria impairment and down-regulation of Drp1 phosphorylation (Fig. 9). The results provide a solid basis for the application of ALT in treating OSCC, with Drp1 being a promising therapeutic target for OSCC.

Fig. 9
figure 9

Diagram of molecular mechanism. Alantolactone inhibits proliferation and promotes apoptosis of oral squamous cell carcinoma cells via impairment of mitochondrial homeostasis and downregulation of Drp1 phosphorylation

Full size image

Conclusions

ALT induced OSCC cell injury via promoting mitochondrial dysfunction and downregulation of Drp1 phosphorylation. Taken together, these findings provide a novel paradigm for the ALT treatment against OSCC, with Drp1 being a promising therapeutic target for OSCC.

Availability of data and materials

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

Abbreviations

ALT:

Alantolactone

ATP:

Adenosine triphosphate

DAF-FM DA:

4-Amino-5-methylamino-2′,7′-difluorofluorescein diacetate

DCFH-DA:

2,7-Dichlorodihydrofluorescein diacetate

Drp1:

Dynamin-related protein 1

MMP:

Mitochondrial membrane potential

MMPRGs:

Mitochondrial metabolic pathways related genes

mtDNA:

Mitochondrial DNA

mtROS:

Mitochondrial reactive oxygen species

MTT:

Methyl thiazolyl tetrazolium

NAC:

N-Acetyl-cysteine

OS:

Oxidative stress

OSCC:

Oral squamous cell carcinoma

p-Drp1:

Phosphorylated-Drp1

RNS:

Reactive nitrogen species

ROS:

Reactive oxygen species

STAT3:

Signal transducers and activators of transcription 3

TCGA:

The Cancer Genome Atlas

TMRM:

Tetramethylrhodamine methyl ester

TOM20:

Translocase of the outer membrane 20

VDAC1:

Voltage-dependent anion channel 1

References

  1. Gangwar SK, Kumar A, Jose S, Alqahtani MS, Abbas M, Sethi G, Kunnumakkara AB. Nuclear receptors in oral cancer-emerging players in tumorigenesis. Cancer Lett. 2022;536: 215666.

    Article  CAS  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  3. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6:92.

    Article  PubMed  Google Scholar 

  4. Warnakulasuriya S, Kerr AR. Oral cancer screening: past, present, and future. J Dent Res. 2021;100:1313–20.

    Article  CAS  PubMed  Google Scholar 

  5. Wang W, Adeoye J, Thomson P, Choi SW. Multiple tumour recurrence in oral, head and neck cancer: characterising the patient journey. J Oral Pathol Med. 2021;50:979–84.

    Article  PubMed  Google Scholar 

  6. Meng X, Lou QY, Yang WY, Wang YR, Chen R, Wang L, Xu T, Zhang L. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun. 2021;41:981–1006.

    Article  Google Scholar 

  7. Sun L, Xu Y, Zhang X, Gao Y, Chen J, Zhou A, Lu Q, Wang Z, Shao K, Wu H, et al. Mesenchymal stem cells functionalized sonodynamic treatment for improving therapeutic efficacy and compliance of orthotopic oral cancer. Adv Mater. 2020;32: e2005295.

    Article  PubMed  Google Scholar 

  8. Valero C, Zanoni DK, Pillai A, Ganly I, Morris LGT, Shah JP, Wong RJ, Patel SG. Host factors independently associated with prognosis in patients with oral cavity cancer. JAMA Otolaryngol Head Neck Surg. 2020;146:699–707.

    Article  PubMed  Google Scholar 

  9. Zahra KF, Lefter R, Ali A, Abdellah EC, Trus C, Ciobica A, Timofte D. The involvement of the oxidative stress status in cancer pathology: a double view on the role of the antioxidants. Oxid Med Cell Longev. 2021;2021:9965916.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res. 2021;787: 108365.

    Article  CAS  PubMed  Google Scholar 

  11. Harris IS, DeNicola GM. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol. 2020;30:440–51.

    Article  CAS  PubMed  Google Scholar 

  12. Zhao RZ, Jiang S, Zhang L, Yu ZB. Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int J Mol Med. 2019;44:3–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32:341–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Xiang S, Zhang K, Yang G, Gao D, Zeng C, He M. Mitochondria-targeted and resveratrol-loaded dual-function titanium disulfide nanosheets for photothermal-triggered tumor chemotherapy. Nanoscale Res Lett. 2019;14:211.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yu H, Li JM, Deng K, Zhou W, Wang CX, Wang Q, Li KH, Zhao HY, Huang SW. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. Theranostics. 2019;9:7033–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265–80.

    Article  CAS  PubMed  Google Scholar 

  18. Gierlikowska B, Gierlikowski W, Demkow U. Alantolactone enhances the phagocytic properties of human macrophages and modulates their proinflammatory functions. Front Pharmacol. 2020;11:1339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Dang X, He B, Ning Q, Liu Y, Guo J, Niu G, Chen M. Alantolactone suppresses inflammation, apoptosis and oxidative stress in cigarette smoke-induced human bronchial epithelial cells through activation of Nrf2/HO-1 and inhibition of the NF-κB pathways. Respir Res. 2020;21:95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gierlikowska B, Gierlikowski W, Bekier K, Skalicka-Woźniak K, Czerwińska ME, Kiss AK. Inula helenium and grindelia squarrosa as a source of compounds with anti-inflammatory activity in human neutrophils and cultured human respiratory epithelium. J Ethnopharmacol. 2020;249: 112311.

    Article  CAS  PubMed  Google Scholar 

  21. Cui L, Bu W, Song J, Feng L, Xu T, Liu D, Ding W, Wang J, Li C, Ma B. Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway. Arch Pharm Res. 2018;41:299–313.

    Article  CAS  PubMed  Google Scholar 

  22. Xu X, Huang L, Zhang Z, Tong J, Mi J, Wu Y, Zhang C, Yan H. Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells. Life Sci. 2019;227:153–65.

    Article  CAS  PubMed  Google Scholar 

  23. Cao P, Xia Y, He W, Zhang T, Hong L, Zheng P, Shen X, Liang G, Cui R, Zou P. Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS. Int J Biol Sci. 2019;15:1676–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang X, Zou S, Ren T, Zhao LJ, Yu LF, Li XY, Yan X, Zhang LJ. Alantolactone suppresses the metastatic phenotype and induces the apoptosis of glioblastoma cells by targeting LIMK kinase activity and activating the cofilin/G-actin signaling cascade. Int J Mol Med. 2021;47:1–13.

    Article  PubMed  Google Scholar 

  25. Kang X, Wang H, Li Y, Xiao Y, Zhao L, Zhang T, Zhou S, Zhou X, Li Y, Shou Z, et al. Alantolactone induces apoptosis through ROS-mediated AKT pathway and inhibition of PINK1-mediated mitophagy in human HepG2 cells. Artif Cells Nanomed Biotechnol. 2019;47:1961–70.

    Article  CAS  PubMed  Google Scholar 

  26. Liu J, Yang Z, Kong Y, He Y, Xu Y, Cao X. Antitumor activity of alantolactone in lung cancer cell lines NCI-H1299 and Anip973. J Food Biochem. 2019;43: e12972.

    Article  PubMed  Google Scholar 

  27. Babaei G, Gholizadeh-Ghaleh Aziz S, RajabiBazl M, Khadem Ansari MH. A comprehensive review of anticancer mechanisms of action of alantolactone. Biomed Pharmacother. 2021;136: 111231.

    Article  CAS  PubMed  Google Scholar 

  28. Muniroh M, Khan N, Koriyama C, Akiba S, Vogel CF, Yamamoto M. Suppression of methylmercury-induced IL-6 and MCP-1 expressions by N-acetylcysteine in U-87MG human astrocytoma cells. Life Sci. 2015;134:16–21.

    Article  CAS  PubMed  Google Scholar 

  29. Okada M, Oba Y, Yamawaki H. Endostatin stimulates proliferation and migration of adult rat cardiac fibroblasts through PI3K/Akt pathway. Eur J Pharmacol. 2015;750:20–6.

    Article  CAS  PubMed  Google Scholar 

  30. Kalaimani L, Devarajan B, Namperumalsamy VP, Veerappan M, Daniels JT, Chidambaranathan GP. Hsa-miR-143-3p inhibits wnt-β-catenin and MAPK signaling in human corneal epithelial stem cells. Sci Rep. 2022;12(1):11432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: redox pathways in molecular medicine. Proc Natl Acad Sci USA. 2018;115:5839–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Maltzman JS. Mitochondria-more than just ATP for CTLs. Sci Immunol. 2021;6: eabn0249.

    Article  PubMed  Google Scholar 

  33. Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:873–98.

    Article  PubMed  Google Scholar 

  34. Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M. Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci. 2017;38:592–607.

    Article  CAS  PubMed  Google Scholar 

  35. He Z, Xu Q, Newland B, Foley R, Lara-Sáez I, Curtin JF, Wang W. Reactive oxygen species (ROS): utilizing injectable antioxidative hydrogels and ROS-producing therapies to manage the double-edged sword. J Mater Chem B. 2021;9:6326–46.

    Article  CAS  PubMed  Google Scholar 

  36. Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64.

    Article  CAS  PubMed  Google Scholar 

  37. Kopinski PK, Singh LN, Zhang S, Lott MT, Wallace DC. Mitochondrial DNA variation and cancer. Nat Rev Cancer. 2021;21:431–45.

    Article  CAS  PubMed  Google Scholar 

  38. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017;117:10043–120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Duan C, Kuang L, Xiang X, Zhang J, Zhu Y, Wu Y, Yan Q, Liu L, Li T. Drp1 regulates mitochondrial dysfunction and dysregulated metabolism in ischemic injury via Clec16a-, BAX-, and GSH- pathways. Cell Death Dis. 2020;11:251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem. 2018;62:341–60.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Rodrigues T, Ferraz LS. Therapeutic potential of targeting mitochondrial dynamics in cancer. Biochem Pharmacol. 2020;182: 114282.

    Article  CAS  PubMed  Google Scholar 

  42. Pei W, Huang X, Ni B, Zhang R, Niu G, You H. Selective STAT3 inhibitor alantolactone ameliorates osteoarthritis via regulating chondrocyte autophagy and cartilage homeostasis. Front Pharmacol. 2021;12: 730312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zhou K, Chen J, Wu J, Wu Q, Jia C, Xu YXZ, Chen L, Tu W, Yang G, Kong J. Atractylenolide III ameliorates cerebral ischemic injury and neuroinflammation associated with inhibiting JAK2/STAT3/Drp1-dependent mitochondrial fission in microglia. Phytomedicine. 2019;59: 152922.

    Article  CAS  PubMed  Google Scholar 

  44. Shi Y, Tao M, Ma X, Hu Y, Huang G, Qiu A, Zhuang S, Liu N. Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy. Cell Death Dis. 2020;11:467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhang Y, Zhang L, Fan K, Gou Y, Zang Z, Ding X, Yang H, Li S. Drp1 regulated mitochondrial hypofission promotes the invasion and proliferation of growth hormone-secreting pituitary adenomas via activating STAT3. Front Oncol. 2022;12: 739631.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Cai Y, Gao K, Peng B, Xu Z, Peng J, Li J, Chen X, Zeng S, Hu K, Yan Y. Alantolactone: a natural plant extract as a potential therapeutic agent for cancer. Front Pharmacol. 2021;12: 781033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhang J, Shen L, Li X, Song W, Liu Y, Huang L. Nanoformulated codelivery of quercetin and alantolactone promotes an antitumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer. ACS Nano. 2019;13:12511–24.

    Article  CAS  PubMed  Google Scholar 

  48. Taneja N, Alam A, Patnaik RS, Taneja T, Gupta S, Sunil MK. Understanding nanotechnology in the treatment of oral cancer: a comprehensive review. Crit Rev Ther Drug Carrier Syst. 2021;38:1–48.

    Article  PubMed  Google Scholar 

  49. Makvandi P, Josic U, Delfi M, Pinelli F, Jahed V, Kaya E, Ashrafizadeh M, Zarepour A, Rossi F, Zarrabi AL. Drug delivery (nano)platforms for oral and dental applications: tissue regeneration, infection control, and cancer management. Adv Sci. 2021;8:2004014.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Professor Zhijun Sun from Wuhan University for providing us with oral cancer cells. We are grateful to the patients who participated in this study.

Funding

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant Number LY21H140003), Wenzhou Science and Technology Bureau (Grant Numbers Y2020116 and Y20190102), National Natural Science Foundation of China (Grant Numbers 81901015 and 82104175), and Foundation for a new star of the medical industry in Zhejiang Province.

Author information

Author notes

  1. Yafei Zhang, Bingqian Yang  and Chenwei Tu contributed equally to this work.

Authors and Affiliations

  1. School and Hospital of Stomatology, Institute of Stomatology, Wenzhou Medical University, Wenzhou, China

    Yafei Zhang, Bingqian Yang, Yifan Ping, Shuhong Chen, Tong Wu, Zheyu Zhao, Yixin Mao, Peng Zou, Zhennan Deng & Xiaoyu Sun

  2. School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China

    Yafei Zhang & Peng Zou

  3. Department of Prosthodontics, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China

    Bingqian Yang, Yifan Ping, Yixin Mao & Zhennan Deng

  4. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China

    Chengwei Tu, Jianmin Li, Kate Huang & Xi Ding

  5. Laboratory for Myology, Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam (VU), Amsterdam Movement Sciences (AMS), Amsterdam, The Netherlands

    Chengwei Tu

  6. Department of Periodontics, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China

    Shuhong Chen, Tong Wu, Zheyu Zhao & Xiaoyu Sun

  7. School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China

    Zhan Yang & Zelin Cao

  8. Department of Oral and Maxillofacial Surgery/Pathology, Amsterdam UMC and Academic Center for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam (VU), Amsterdam Movement Science (AMS), Amsterdam, The Netherlands

    Gang Wu

  9. Department of Oral Cell Biology, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam (UvA) and Vrije Universiteit Amsterdam (VU), Amsterdam, The Netherlands

    Gang Wu

Authors
  1. Yafei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bingqian Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chengwei Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yifan Ping
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuhong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zheyu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yixin Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zelin Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jianmin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kate Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xi Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Gang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Peng Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Zhennan Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Xiaoyu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BY, XS, PZ contributed to the conception of the study; YZ, BY, YP, SC, TW, ZZ performed the experiment; CT, YM, ZY, ZC, JL contributed significantly to analysis and manuscript preparation; YZ, BY, XS performed the data analyses and wrote the manuscript; KH, XD, WG, ZD helped perform the analysis with constructive discussions. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Peng Zou, Zhennan Deng or Xiaoyu Sun.

Ethics declarations

Ethics approval and consent to participate

This study was approved by Wenzhou Medical University’s Research Ethics Committee (KY2022-R156).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Statistical analysis of the level of mitochondrial proteins in OSCC cancer tissues.The corresponding statistical analysis of P-Drp1/GAPDH.The statistical analysis of Drp1/GAPDH.The statistical analysis of P-Drp1/Drp1.The statistical analysis of TOM20/GAPDH.The statistical analysis of VDAC1/GAPDH.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Yang, B., Tu, C. et al. Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells. J Transl Med 21, 328 (2023). https://doi.org/10.1186/s12967-023-04188-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12967-023-04188-2

Keywords

Journal of Translational Medicine

ISSN: 1479-5876

Contact us